However, there was no agreement within the HCP panel whether prostate cancer risk and PSA testing should be proactively discussed with asymptomatic men aged ≥50 years, in the absence of any other prostate cancer risk factors. This evidence concerns the gene KLK3 and Familial prostate cancer.